Phil Nadeau
Stock Analyst at TD Cowen
(2.83)
# 1,650
Out of 5,115 analysts
24
Total ratings
52.17%
Success rate
35.12%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $175 → $200 | $146.93 | +36.12% | 1 | Dec 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $50 → $45 | $25.16 | +78.86% | 1 | Oct 31, 2025 | |
| KURA Kura Oncology | Reiterates: Buy | n/a | $11.06 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $112.27 | -42.10% | 2 | Nov 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $300 → $275 | $176.33 | +55.96% | 6 | Oct 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $60.16 | +99.47% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $462.99 | +7.99% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $16.72 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $13.87 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $5.88 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.18 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.36 | - | 1 | Jul 16, 2018 |
Neurocrine Biosciences
Dec 5, 2025
Maintains: Buy
Price Target: $175 → $200
Current: $146.93
Upside: +36.12%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $25.16
Upside: +78.86%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $11.06
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $112.27
Upside: -42.10%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300 → $275
Current: $176.33
Upside: +55.96%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $60.16
Upside: +99.47%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $462.99
Upside: +7.99%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $16.72
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.87
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.88
Upside: -
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.18
Upside: -
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $6.36
Upside: -